SleepMed Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • SleepMed's estimated annual revenue is currently $107.4M per year.(i)
  • SleepMed's estimated revenue per employee is $251,000

Employee Data

  • SleepMed has 428 Employees.(i)
  • SleepMed grew their employee count by -6% last year.

SleepMed's People

NameTitleEmail/Phone
1
Benefits/Payroll ManagerReveal Email/Phone
2
Sr. Systems EngineerReveal Email/Phone
3
Territory Manager/Sleep SpecialistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$26.1M1040%$63.5MN/A
#2
$14.3M57-8%N/AN/A
#3
$33.1M1326%N/AN/A
#4
$10.8M435%N/AN/A
#5
$488.3M12160%N/AN/A
#6
$14.3M5710%N/AN/A
#7
$5M20-9%N/AN/A
#8
$95.6M381-1%N/AN/A
#9
$16.8M673%N/AN/A
#10
$57M22713%N/AN/A
Add Company

What Is SleepMed?

SleepMed was formed in December 1999 through the merger of Sleep Disorder Centers of America (SDCA), based in Columbia, SC, and DigiTrace Care Services, Inc. (DCSI), based in Boston, MA. SDCA was founded in 1994 by David Lewis and Dr. Richard Bogan , who has board certifications in sleep medicine, pulmonary medicine, critical care medicine and internal medicine.

keywords:N/A

N/A

Total Funding

428

Number of Employees

$107.4M

Revenue (est)

-6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

SleepMed News

2022-04-17 - Sleeping Aids Market Industry Future Growth During the ...

SleepMed Inc. Cadwell Teva Pharmaceutical Industries Ltd. Natus Medical Inc. Compumedics Ltd. DeVilbiss Healthcare LLC.

2022-04-17 - Several Acupuncture Therapies Improve Sleep Quality Scores ...

... of multiple acupuncture therapies for primary insomnia: a systematic review and network meta-analysis of randomized trial. Sleep Med.

2022-04-13 - Sleep Aids Market – Blackswan Real Estate

Koninklijke Philips, Merck, Sanofi, DeVilbiss Healthcare, Pfizer, SleepMed, Cadwell Laboratories, Compumedics, Natus Medical, GlaxoSmithKline.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$80.6M4307%N/A
#2
$96M4323%N/A
#3
$146.1M4338%N/A
#4
$98.9M4527%N/A
#5
$165.3M456-1%N/A